First 2 doses free, next 3 Oestrogen doses positive Aus and paid by March May Fulvestrant 11 Yes metastatic 20 no funding no funding no funding no funding NZ then 2006 2006 breast patient, cancer then all free No outside outside No April July Jan Gefitinib Iressa® Aus 2 No 0 funding Aug 2012 funding response 2003 2004 first 2004 restrictions restrictions line July 2013 rejected Relapsed or for chronic refractory mantle cell lymphoma; leukaemia no Aus and chronic April and registration July no Ibrutinib 18 Yes 44 None no funding NZ lymphocytic 2015 no 2015 registration leukaemia; funding small lymphoma lymphocytic lymphoma July 2015 (deferred Nov 2015)
registration Fulvestrant Aus and NZ 11 Yes Oestrogen positive metastatic breast cancer 20 First 2 doses free, next 3 doses paid by then patient, then all free March 2006 no funding no funding May 2006 no funding no funding Gefitinib Iressa® Aus 2 No No response 0 No April 2003 July 2004 first line July 2013 outside funding restrictions Jan 2004 Aug 2012 outside funding restrictions Ibrutinib Aus and NZ 18 Yes Relapsed or refractory mantle cell lymphoma; chronic lymphocytic leukaemia; small lymphocytic lymphoma 44 None April 2015 for chronic leukaemia and lymphoma July 2015 (deferred Nov 2015) no no funding July 2015 no funding no registration rejected
1-s2.0-S0168851017303457-mmc1.docx